Evidence map›Paper›PMID 40491931›Full record

ArticleOpen forum infectious diseases2025

Sequencing HIV Diagnostic Samples to Detect Genetic Clusters and Assess Sequence Coverage Gaps.

Cara J Broshkevitch, Shuntai Zhou, Annalea Greifinger, Kimberly Enders, Nathan Long, Erika Samoff, Kimberly A Powers, Victoria Mobley, Simon D W Frost, Erik Volz and 5 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Cara J BroshkevitchDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-5627-8250
Shuntai ZhouLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-8353-386X
Annalea GreifingerDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Kimberly EndersDepartment of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Nathan LongLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Erika SamoffDivision of Public Health, North Carolina Department of Health and Human Services, Raleigh, North Carolina, USA.
Kimberly A PowersDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Victoria MobleyDivision of Public Health, North Carolina Department of Health and Human Services, Raleigh, North Carolina, USA.
Simon D W FrostMicrosoft Premonition, Microsoft Strategic Missions and Technologies, Redmond, Washington, USA.
Erik VolzDepartment of Infectious Disease Epidemiology, Imperial College London, London, UK.ORCID https://orcid.org/0000-0001-6268-8937
Scott ShoneDivision of Public Health, North Carolina Department of Health and Human Services, Raleigh, North Carolina, USA.
Joseph J EronDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID https://orcid.org/0000-0002-4938-0644
Myron S CohenInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ronald SwanstromLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Ann M DennisDivision of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Funding

Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Training in Sexually Transmitted Infections and HIVT32AI007001 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SENA-SOBERANO, ARLENE C. · 1985 to 2025
$10.9M
HIV Evolution Defines Virus-Host/Drug Interactions In Viremic and Aviremic PeopleR01AI140970 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ronald I Swanstrom, Shuntai Zhou · 2018 to 2026
$4.1M
Timely monitoring and response to HIV transmission networks for intensified preventionR01AI135970 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DENNIS, ANN · 2018 to 2022
$3.8M
Rapid Response to Incident HIV Infection through Social Network Strategies and Molecular Epidemiology to Inform Partner ServicesR01AI169602 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Ann Dennis · 2022 to 2026
$3.6M
NIAID NIH HHS P30 AI050410NIAID NIH HHS R01 AI135970NIAID NIH HHS R01 AI140970NIAID NIH HHS R01 AI169602NIAID NIH HHS T32 AI007001
6 · The paper itself

Abstract

Background: HIV molecular cluster detection in the United States relies on HIV sequences obtained from drug resistance testing during clinical care ("routine care sequences"). This approach misses people who are not linked to care or who receive care but have uncollected or unreported sequences. Methods: We collected "HIV test sequences" from remnant serum samples of people testing newly positive from 2018 through 2021 by a large public health laboratory in North Carolina. We incorporated the HIV test sequences into a statewide molecular cluster analysis and assessed impact on "active cluster" detection (≥5 members newly diagnosed). We described data gaps filled by HIV test sequences, comparing (1) the extent of care sequence missingness due to gaps in care linkage vs sequence collection or reporting and (2) the characteristics of people with an HIV test sequence who had a care sequence, care but no care sequence, or no evidence of care. Results: Of 19 770 people included in the cluster analysis, 847 had an HIV test sequence, one-third of whom had no routine care sequence. We identified 13 additional active clusters (a 33% relative increase) and 40 larger active clusters after incorporating HIV test sequences. Most people with an HIV test sequence but no care sequence (78%) had another care indicator, suggesting sequence undercollection or underreporting, but a fifth (22%) had no evidence of care. Conclusions: Higher sequence coverage can improve cluster detection. While increased routine care sequence collection and reporting could fill many data gaps, sequencing remnant HIV test samples could include people without care linkage.

Indexed as

HIVHIV diagnosismolecular epidemiologysequencetransmission cluster

Identifiers

PMID40491931
PMCPMC12147020

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.